Hepatic encephalopathy pathophysiology

Jump to navigation Jump to search

Hepatic encephalopathy Microchapters

Home

Patient Information

Overview

Historical Perspective

Classification

Pathophysiology

Causes

Differentiating Hepatic Encephalopathy from other Diseases

Epidemiology and Demographics

Risk Factors

Screening

Natural History, Complications and Prognosis

Diagnosis

History and Symptoms

Physical Examination

Laboratory Findings

X Ray

CT

MRI

Ultrasound

Other Imaging Findings

Other Diagnostic Studies

Treatment

Medical Therapy

Surgery

Primary Prevention

Secondary Prevention

Cost-Effectiveness of Therapy

Future or Investigational Therapies

Case Studies

Case #1

Hepatic encephalopathy pathophysiology On the Web

Most recent articles

Most cited articles

Review articles

CME Programs

Powerpoint slides

Images

American Roentgen Ray Society Images of Hepatic encephalopathy pathophysiology

All Images
X-rays
Echo & Ultrasound
CT Images
MRI

Ongoing Trials at Clinical Trials.gov

US National Guidelines Clearinghouse

NICE Guidance

FDA on Hepatic encephalopathy pathophysiology

CDC on Hepatic encephalopathy pathophysiology

Hepatic encephalopathy pathophysiology in the news

Blogs on Hepatic encephalopathy pathophysiology

Directions to Hospitals Treating Hepatic encephalopathy

Risk calculators and risk factors for Hepatic encephalopathy pathophysiology

Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1] Associate Editor(s)-in-Chief: Mohamadmostafa Jahansouz M.D.[2]

Overview

Due to the presence of scarring within the liver, cirrhosis leads to obstruction of the passage of blood through the liver causing portal hypertension. This means it is difficult for blood from the intestines to go through the liver to get back to the heart. Portal-systemic anastamoses ("shunts") develop, and portal blood (from the intestinal veins) will bypass the liver and return to the heart via another route without undergoing first-pass detoxification by the liver. The toxic substances which accumulate in the setting of liver failure and affect the brain have been thought to include ammonia (NH3) and mercaptans. Ammonia is normally converted to urea by the liver and, as with mercaptans, is produced by the bacterial breakdown of protein in the intestines. Ammonia can cross the blood-brain barrier, where it causes the support cells of the brain (astrocytes) to swell. The swelling of the brain tissue increases intracranial pressure, and can lead to coma or death via herniation of the brainstem. Disorders and conditions such as alcoholic liver disease, hepatitis C, hepatitis B, hemochromatosis, Wilson disease, age above 50 years and male gender may lead to hepatic encephalopathy.

Pathophysiology

Pathogenesis

Following important aspects about pathophysiology of hepatic encephalopathy:[1][2][3][4]

Genetics

There is no established relation between hepatic encephalopathy and genetic inheritance.

Associated Conditions

Any disorders with liver failure may lead to hepatic encephalopathy.

Microscopic Pathology

Microscopic studies of specimens from patients with hepatic encephalopathy suggests:[3]

References

  1. Frederick RT (2011). "Current concepts in the pathophysiology and management of hepatic encephalopathy". Gastroenterol Hepatol (N Y). 7 (4): 222–33. PMC 3127024. PMID 21857820.
  2. Jones EA (2000). "Pathogenesis of hepatic encephalopathy". Clin Liver Dis. 4 (2): 467–85. PMID 11232201.
  3. 3.0 3.1 Cordoba J (2014). "Hepatic Encephalopathy: From the Pathogenesis to the New Treatments". ISRN Hepatol. 2014: 236268. doi:10.1155/2014/236268. PMC 4890879. PMID 27335836.
  4. Aldridge DR, Tranah EJ, Shawcross DL (2015). "Pathogenesis of hepatic encephalopathy: role of ammonia and systemic inflammation". J Clin Exp Hepatol. 5 (Suppl 1): S7–S20. doi:10.1016/j.jceh.2014.06.004. PMC 4442852. PMID 26041962.
  5. Schuppan D, Afdhal NH (2008). "Liver cirrhosis". Lancet. 371 (9615): 838–51. doi:10.1016/S0140-6736(08)60383-9. PMC 2271178. PMID 18328931.
  6. Nusrat S, Khan MS, Fazili J, Madhoun MF (2014). "Cirrhosis and its complications: evidence based treatment". World J Gastroenterol. 20 (18): 5442–60. doi:10.3748/wjg.v20.i18.5442. PMC 4017060. PMID 24833875.
  7. Zhou WC, Zhang QB, Qiao L (2014). "Pathogenesis of liver cirrhosis". World J Gastroenterol. 20 (23): 7312–24. doi:10.3748/wjg.v20.i23.7312. PMC 4064077. PMID 24966602.
  8. Nguyen DL, Morgan T (2014). "Protein restriction in hepatic encephalopathy is appropriate for selected patients: a point of view". Hepatol Int. 8 (2): 447–51. doi:10.1007/s12072-013-9497-1. PMC 4267851. PMID 25525477.
  9. Ferenci P (2017). "Hepatic encephalopathy". Gastroenterol Rep (Oxf). 5 (2): 138–147. doi:10.1093/gastro/gox013. PMC 5421503. PMID 28533911.
  10. Klempnaue J, Schrem H (2001). "Review: surgical shunts and encephalopathy". Metab Brain Dis. 16 (1–2): 21–5. PMID 11726084.

Template:WH Template:WS